Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis

Sponsor
Anders Svenningsson
Study ID
NCT01719159
Phase
PHASE2
Status
Completed

Conditions

  • Progressive Multiple Sclerosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.

Study Details

This is a is a small scale open phase two interventional study to assess long-term stabilising effects of on neurological symptoms by regular intrathecal administered monoclonal antibodies in progressive multiple sclerosis.

Key Dates

Start date
Nov 30, 2009
Status verified
Nov 2016
Primary completion
Jun 30, 2016
Completion
Jun 30, 2016

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rituximab
    Rituximab, 25 mg, is administrated intrathecal three times one week apart

Primary Outcome Measure

Number of participants with adverse events [ Time Frame: One year after completed treatment ]

Related Studies